CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
| Revenue (TTM) | $400.05M |
| Gross Profit (TTM) | $367.50M |
| EBITDA | $228.81M |
| Operating Margin | 50.00% |
| Return on Equity | 65.60% |
| Return on Assets | 26.40% |
| Revenue/Share (TTM) | $5.29 |
| Book Value | $5.58 |
| Price-to-Book | 1.36 |
| Price-to-Sales (TTM) | 1.44 |
| EV/Revenue | 1.405 |
| EV/EBITDA | 2.54 |
| Quarterly Earnings Growth (YoY) | 42.80% |
| Quarterly Revenue Growth (YoY) | 226.10% |
| Shares Outstanding | $78.45M |
| Float | $66.53M |
| % Insiders | 7.53% |
| % Institutions | 54.58% |
Volatility is currently expanding
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to 2028, driven by DefenCath adoption and pipeline progress. Key mid-to-long-term catalysts include potential DaVita onboarding, federal market expansion, and pipeline assets like DefenCath TPN and REZZAYO.
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath utilization through changes in federal reimbursement.
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets Global Healthcare Conference being held in New York on May 19 – 20, 2026 and the Jefferies Global Healthcare Conference being held in New York on June 2 – 4, 2026. Details for each fireside chat is as follows:
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRMD and any ticker you trade — then tracks every position and per-strategy win rate.
